Simulations Plus, Inc. (SLP)
NASDAQ: SLP · Real-Time Price · USD
29.75
-1.15 (-3.72%)
Oct 29, 2024, 4:00 PM EDT - Market closed
Simulations Plus Revenue
In the fiscal year ending August 31, 2024, Simulations Plus had annual revenue of $70.01M with 17.52% growth. Simulations Plus had revenue of $18.70M in the quarter ending August 31, 2024, with 19.65% growth.
Revenue (ttm)
$70.01M
Revenue Growth
+17.52%
P/S Ratio
8.49
Revenue / Employee
$355,396
Employees
197
Market Cap
596.52M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Aug 31, 2024 | 70.01M | 10.44M | 17.52% |
Aug 31, 2023 | 59.58M | 5.67M | 10.52% |
Aug 31, 2022 | 53.91M | 7.44M | 16.01% |
Aug 31, 2021 | 46.47M | 4.88M | 11.73% |
Aug 31, 2020 | 41.59M | 7.62M | 22.43% |
Aug 31, 2019 | Pro | Pro | Pro |
Aug 31, 2018 | Pro | Pro | Pro |
Aug 31, 2017 | Pro | Pro | Pro |
Aug 31, 2016 | Pro | Pro | Pro |
Aug 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Orthofix Medical | 771.65M |
Pharming Group | 285.75M |
Entrada Therapeutics | 239.40M |
Cytek Biosciences | 197.71M |
OrthoPediatrics | 175.07M |
Standard BioTools | 136.30M |
CureVac | 70.57M |
Stoke Therapeutics | 15.16M |
SLP News
- 6 days ago - Simulations Plus, Inc. (SLP) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Simulations Plus Reports Fourth Quarter and Fiscal 2024 Financial Results - Business Wire
- 20 days ago - Simulations Plus Announces Fourth Quarter and Fiscal Year 2024 Earnings and Conference Call Date - Business Wire
- 21 days ago - Simulations Plus and the University of Southern California Secure NIH Grant to Develop New AI Drug Discovery Offerings - Business Wire
- 2 months ago - Simulations Plus to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - Business Wire
- 2 months ago - Simulations Plus Optimizes Business Unit Structure to Support Future Growth Following Recent Strategic Acquisitions - Business Wire
- 3 months ago - Simulations Plus Releases DILIsym® X - Business Wire
- 3 months ago - Simulations Plus Releases ADMET Predictor® Version 12 - Business Wire